Sodium-glucose transporter type 2 (SGLT2) inhibitors have been shown to confer substantial kidney and cardiovascular benefits among patients with type 2 diabetes, heart failure, and/or high-risk CKD [5, 6]. This evidence concerns the gene SLC5A2 and chronic kidney disease.